postbiotics - OmicsDI

Show results for

Unknown (245)
Genomics (72)
Proteomics (16)
Metabolomics (4)
Transcriptomics (3)

Organisms

Andropogon gerardi (14)
Bacteria (14)
Canis lupus familiaris (14)
Clostridium perfringens (14)
Cnidaria (14)
Cricetulus griseus (14)
Eukaryota (14)
Fasciola (14)
Hepatitis B virus (14)
Human betaherpesvirus 5 (14)
Madurella mycetomatis (14)
Mesocricetus auratus (14)
Miscanthus x giganteus (14)
Mus musculus (14)
Mycobacterium tuberculosis (14)
Orthoflavivirus (14)
Panicum virgatum (14)
Platyhelminthes (14)
Pseudomonas aeruginosa AES-1R (14)
Rattus norvegicus (14)
Saccharomyces cerevisiae (14)
Schizosaccharomyces pombe (14)
Severe acute respiratory syndrome coronavirus 2 (14)
Shigella (14)
Sorghastrum nutans (14)
Streptococcus dysgalactiae subsp. equisimilis SK1249 (14)
Homo sapiens (2)
Bos taurus (1)
Mus musculus (1)
Bifidobacterium bifidum (1)

Organisms

Lactiplantibacillus plantarum (2)
Homo sapiens (2)
Lactococcus taiwanensis (1)
Leuconostoc suionicum (1)
human skin metagenome (1)
human feces metagenome (1)
Gallus gallus (1)
human metagenome (1)
mouse gut metagenome (1)
Bos taurus (1)
human gut metagenome (1)
Mus musculus (1)

Repository

ENA (72)
pride (14)
MetaboLights (4)
geo (3)
iProX (1)
jPOST (1)

Tissue

Cell culture (7)
Epithelial cell (2)
Stomach (1)

Disease

Lymphoma (2)
Stomach cancer (2)
Gastric adenocarcinoma (1)

Technology Type

Mass Spectrometry (14)
Bottom-up proteomics (12)
Mass spectrometry (2)
Mass spectrometry assay (2)
Data-dependent acquisition (2)
Data-independent acquisition (1)
Gel-based experiment (1)
SWATH MS (1)
Shotgun proteomics (1)

Instrument Platform

Liquid Chromatography MS - negative - hilic (2)
Liquid Chromatography MS - positive - hilic (2)
Liquid Chromatography MS - positive - reverse-phase (1)
Liquid Chromatography MS - negative - reverse-phase (1)
Liquid Chromatography MS - positive - reverse phase (1)

Metabolite Name

UDP-2-acetamido-3-amino-2,3-dideoxy-alpha-D-glucurote (1)
Thiadiazolidinone (1)
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/O-18:0) (1)
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/O-18:0) (1)
TG(22:4(7Z,10Z,13Z,16Z)/O-18:0/22:4(7Z,10Z,13Z,16Z)) (1)
TG(20:3(5Z,8Z,11Z)/O-18:0/20:3(5Z,8Z,11Z)) (1)
TG(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/O-18:0) (1)
TG(18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/O-18:0) (1)
TG(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/O-18:0) (1)
TG(18:1(11Z)/O-18:0/18:1(11Z)) (1)
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/O-18:0) (1)
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/O-18:0) (1)
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/O-18:0) (1)
TG(15:0/22:1(13Z)/O-18:0) (1)
TG(15:0/18:4(6Z,9Z,12Z,15Z)/O-18:0) (1)
TG(15:0/18:2(9Z,12Z)/O-18:0) (1)
TG(14:0/22:2(13Z,16Z)/O-18:0) (1)
TG(14:0/22:0/O-18:0) (1)
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/O-18:0) (1)
TG(14:0/20:2n6/O-18:0) (1)
TG(14:0/18:3(6Z,9Z,12Z)/O-18:0) (1)
TG(14:0/15:0/O-18:0) (1)
Tetracozole (1)
SOFMPBOQLPVEQZ-OWMASPSUSA-N (1)
S-(1,2-Dichlorovinyl)-L-cysteine (1)
Ritovir (1)
Quipril (1)
PS(18:4(6Z,9Z,12Z,15Z)/5-iso PGF2VI) (1)
PS(14:1(9Z)/5-iso PGF2VI) (1)
Potassium dichromate (1)

First Public Date

2026 (27)
2025 (21)
2023 (10)
2024 (8)
2022 (4)
2021 (1)
2020 (1)

Release Date

2025 (65)
2024 (50)
2022 (43)
2023 (40)
2021 (24)
2026 (8)
2020 (8)
2019 (6)
2018 (1)

Lab affiliation

NICM Health Research Institute, Western Sydney University (3)
NICM HRI, Western Sydney University (2)
Aarhus University (1)
Department of Biology, Maynooth University, Maynooth, Co. Kildare, Ireland; (1)
Department of Comparative Biochemistry and Bioanalytics, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Poland (1)
Department of Comparative Biochemistry and Bioanalytics, Faculty of Biochemistry, Biophysicsand Biotechnology, Jagiellonian University (1)
Institute of Biomedical Chemistry (1)
Karolinska Institutet (1)
NICM HRI, Western Sydney University, NSW, Australia (1)
Proteomic, Metabolomic and Mass Spectrometry LAB, ISPAAM, NATIONAL RESEARCH COUNCIL (1)
Proteomics, Metabolomics and Mass Spectrometry Laboratory Institute for Animal Production Systems in Mediterranean Environments (ISPAAM) National Research Council (CNR) Piazzale Enrico Fermi 1, 80055 Portici (NA) ITALY (1)

Publication date

2025 (11)
2024 (6)
2026 (6)

Tags

xref:PubMed:40646804 (1)
xref:PubMed:39531335 (1)

Previous page
1 / 34
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 34
Next page

Sort by:

Relevance

Page size

Untargeted metabolomics profiling of gut metabolites in loperamide-induced constipation mice intervened by postbiotics

This study performed untargeted metabolomics to investigate alterations of intestinal metabolites in loperamide-induced constipated mice. We aimed to characterize metabolic responses after intervention with postbiotics, and explore key metabolites correlated with constipation-relieving effects.

2026-07-29 | MTBLS15188 | MetaboLights

Gut microbial postbiotics as potential therapeutics for lymphoma: Proteomics Insights of the synergistic effects of Nisin and Urolithin B against human lymphoma cells

Lymphoma remains a substantial global health concern, necessitating innovative therapeutic strategies. The emerging role of gut microbiota-derived metabolites, known as postbiotics, offers promising avenues for cancer treatment. This study evaluated the antiproliferative activities of various postbi...

ORGANISM(S): Homo sapiens (Human)

2025-07-19 | PXD063948 | Pride

Short-chain fatty acids synergistically interact with doxorubicin against gastric adenocarcinoma cells

Short-chain fatty acids (SCFAs) are microbial metabolites, also known as postbiotics, produced by the gut microbiotame, playing essential rolesessential in maintaining gut health and exerting potential anticancer effects. This study investigates the antiproliferative effects of short-chain fatty aci...

ORGANISM(S): Homo sapiens (Human)

2026-01-19 | PXD061824 | Pride

Postbiotics Apoptosis Doxorubicin Proteomics Gastric cancer

The use of omics technologies in creating LBP and postbiotics based on the Limosilactobacillus fermentum U-21

In recent years, there has been an increasing tendency to create drugs of various types based on certain commensal bacteria of the human microbiota and their ingredients. This primarily concerns live biotherapeutics (LBPs) and postbiotics. The creation of such drugs, which can be called pharmacobiot...

ORGANISM(S): Limosilactobacillus fermentum

2024-06-04 | PXD050857 | Pride

Pharmabiotics Metabolome Omics technologies Limosilactobacillus fermentum u-21 Proteome Postbiotics

Postbiotics and Kidney Disease.

Not available

S-EPMC9501217 | biostudies-literature

The Current and Future Perspectives of Postbiotics.

Not available

S-EPMC9913028 | biostudies-literature

Postbiotics in rheumatoid arthritis: emerging mechanisms and intervention perspectives.

Not available

S-EPMC10662086 | biostudies-literature